交叉耐药性

耐四环素的Uu和Mh株对多西环素、米诺环素、交沙霉素以及氧氟沙星存在交叉耐药性。

The tetracycline-resistant Uu or Mh showed cross resistance to doxycycline , minocycline , josamycin and ofloxacin .

差异有统计学意义（P0.05），表明耐药细胞对其他机制不同、结构各异的化疗药均有不同程度交叉耐药性。

The difference was statistically significant ( P0.05 ) . Show that resistant cells to other different mechanism , structure to some extent effective cross resistance .

CCK-8法测定SGC7901/DDP细胞的耐药指数及交叉耐药性。

The resistance index and cross-resistance characteristics of SGC7901 / DDP cells was detected by CCK-8 assay .

背景：多药耐药（MultidrugResistance，MDR）是指肿瘤对未接触过的、结构不同、靶位各异的多种抗肿瘤药物也具有交叉耐药性。

Background : Multidrug resistance ( MDR ) is characterized by a cross-resistant phenotype against several unrelated drugs that differ widely with respect to molecular structure and target specificity .

临床试验表明，TPT与顺铂和紫杉醇无交叉耐药性。

Clinical non cross resistance had been demonstrated between TPT and cisplatin or paclitaxel .

大肠埃希菌对氟喹诺酮类药物存在交叉耐药性，且产ESBLs的大肠埃希菌对氟喹诺酮类药物存在相关耐药。

The cross-resistance of E. coli to fluoroquinolones exists and the associated resistance of ESBLs-producing E. coli to fluoroquinolones exists . 3 .

多药耐药性（MultidrugResistance，MDR）是指肿瘤细胞对一种药物产生耐药性，同时对结构与作用机理不同的药物也产生交叉耐药性。

Multidrug resistance ( MDR ) is defined as the ability of tumor cells exposed to single drug to develop resistance to a broad range of structurally and functionally unrelated drugs .

耐替米考星的S6和BG44T菌株对红霉素、泰乐菌素、林可霉素有交叉耐药性。

Tilmicosin-resistant S6 and BG44T showed cross-resistance to erythromycin , tylosin and lincomycin .

作者认为MVP方案对NSCLC有较好疗效，且VDS与VCR无完全交叉耐药性。

In author 's opinion , MVP program is more effective for NSCLC . Besides , complete cross resistance do not occur when VDS and VCR are used .

结论：产ESBL细菌分布广泛、阳性率高，易借助耐药质粒传播，具有较高的交叉耐药性和多重耐药性。

Conclusion : ESBL production distribute broad , are detected positive frequently and spread easily by resistant plasmid . It 's cross resistance and multi-resistance are high .

目的：P53基因与大肠癌化疗药敏关系密切，而羟基喜树碱（HCPT）因其与5FU无交叉耐药性而被逐渐用于治疗进展期大肠癌。

Objective : P53 gene has a close relationship with the chemosensitivity of colorectal cancer , Hydroxyl Camptothecin ( HCPT ) which lacks of cross resistance with 5 FU has been reported to treat advanced colorectal cancers recently .

1996年FDA批准治疗小细胞肺癌（SCLC）和卵巢癌（OVC）。临床试验表明，TPT与顺铂和紫杉醇无交叉耐药性。

FDA approved TPT as a treatment drug for small cell lung cancer ( SCLC ) and ovarian cancer ( OVC ) in 1996 . Clinical non cross resistance had been demonstrated between TPT and cisplatin or paclitaxel .

结论产ESBLs细菌具有较高的交叉耐药性，通过耐药质粒可传递给其他细菌，实验室应积极开展ESBLs的检测，并向临床及时报告。

CONCLUSION Producing ESBL strains are of high cross-resistance to the commonly used antibiotics , and the resistance can be transfered to other bacteria by resistant plasmid . It is suggested that clinical lab should positively develop the ESBLs examinations and report the results to clinic in time .

10-羟基喜树碱（10-hydroxycamptothecin，HCPT）是从喜树中提取到的生物碱或半合成品，抗瘤谱广，与其它常用抗肿瘤药无交叉耐药性，因此对耐药肿瘤也有治疗作用[1]。

HCPT ( 10-hydroxycamptothecin ) is a kind of the alkaloids or semi-synthetics which is extracted from the camptotheca acuminata , it has broad spectrum of anti-tumor , without cross-resistance with other commonly used anticancer drugs , so it also has the effect on the drug-resistant tumors .

由此可见，两种药物并不存在必然的交叉耐药性。

So there were certainly no cross-drug-resistance to Diclazuril and Toltrazuril .

诱导出的高度耐药株对氟喹诺酮类之间存在交叉耐药性。

The cross-resistance of induced high resistant strains to fluoroquinolones exists .

莫西沙星与左氧氟沙星对结核分枝杆菌的交叉耐药性研究

Study on the cross-resistance of moxifloxacin and levofloxacin in Mycobacterium tuberculosis

禽致病性大肠杆菌对氟喹诺酮类药物交叉耐药性研究

Studies on cross-resistance of avain Escherichia coli to fluoroquinolones

结论：白血病细胞对上述两种药物有交叉耐药性。

Conclusion : The results indicated that there was cross resistance between DNR and Harr for AML cells .

但是出于交叉耐药性的考虑，欧盟从1999年起已经禁止在饲料中使用维吉尼亚霉素。

For cross-resistance considerations , the European Union has banned the use of virginiamycin in animal feed since 1999 .

33株临床分离菌株的耐药性较为严重，存在交叉耐药性和多重耐药性现象。

The drug resistance to 33 strains isolated from clinical samples was severe , and multidrug resistance and cross resistance were existent .

鉴于其独特的作用机理，恶唑烷酮类抗菌剂很少与其它类抗菌剂产生交叉耐药性。

Due to its unique mechanism of action , there are fewer cross-resistances between the oxazolidinones and other families of antibacterial agents .

泛耐药铜绿假单胞菌肺炎危险因素及护理对策喹诺酮类药物与碳青霉烯类药物之间的交叉耐药性和泛耐药性的研究

Risk factors of nosocomial pneumonia due to pan-drug resistant pseudomonas aeruginosa : a case-control study Cross drug resistance and extensive drug resistance with Quinolones and Carbapenems

分别采用地克珠利和百球清饮水剂对3株来源和特性不同的柔嫩艾美耳球虫株进行了交叉耐药性检验。

The cross-drug-resistance of three kinds of different source and characteristic strains in Eimeria tenella were tested by means of Diclazuril solution and Toltrazuril solution respectively .

抗菌肽具有广谱、高效抗菌活性，与其他抗菌药物多无交叉耐药性，而且不易诱导耐药菌株的产生。

Antimicrobial peptides have broad-spectrum , high-effective antibacterial activity and without cross-resistance with other kinds of antimicrobial agents , and not induced the emerge of drug-resistant strains .

喹诺酮类药物具有抗菌谱广、菌活性强、药方便，与常用抗菌药物无交叉耐药性、格低等特点。

Quinolone is known as broad antibacterial spectrum , high potency , no crossing drugresistance with other antibacterial drugs , and easy and low cost to administer .

头孢克肟抗菌谱广、半衰期长、交叉耐药性小、用药剂量小、适应症广泛。

Cefixime is characterized by broad spectrum , long half life period , less cross resistance to chemical reagent , small use dosage and wide scope of application .

其独特的环脂肽结构及作用机制，使其将不会受到来自其它抗生素所致交叉耐药性的影响，具有广阔的市场前景。

Due to its unique cyclic lipopeptide structure and mechanism of action , it will not generate cross-resistance from other approved antibiotics , instead , has a broad market prospect .

报道其配合物的抗肿瘤活性、限量毒性、交叉耐药性和其中四种配合物的Ⅱ期临床结果。

The antitumor activities , dose-limiting toxicities and cross-resistances of several Pt complexes which have entered into phase I clinical trials and phase II clinical of 4 of them are reported .

研究抗癌机理与顺铂和卡铂不同的新型铂配合物是增加该类药物的抗肿瘤活性和克服交叉耐药性的途径之一。

Investigation on novel Pt complexes with different anticancer 's mechanisms from Cisplatin and Carboplatin is one of ways to increase the anticancer activities of Pt drugs and to overcome their cross-resistances .